Low-Density Lipoprotein Cholesterol Testing Following Myocardial Infarction Hospitalization Among Medicare Beneficiaries
JACC: Advances · 2024-01 · 3 (1) · 100753
DOI: 10.1016/j.jacadv.2023.100753 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Advances, 2024-01. Verfasst von Lisandro D Colantonio und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen Inc.
Abstract (Originalsprache)
Background
Low-density lipoprotein cholesterol (LDL-C) is used to guide lipid-lowering therapy after a myocardial infarction (MI). Lack of LDL-C testing represents a missed opportunity for optimizing therapy and reducing cardiovascular risk.
Objectives
The purpose of this study was to estimate the proportion of Medicare beneficiaries who had their LDL-C measured within 90 days following MI hospital discharge.
Methods
We conducted a retrospective cohort study of Medicare beneficiaries ≥66 years of age with an MI hospitalization between 2016 and 2020. The primary analysis used data from all beneficiaries with fee-for-service coverage and pharmacy benefits (532,767 MI hospitalizations). In secondary analyses, we used data from a 5% random sample of beneficiaries with fee-for-service coverage without pharmacy benefits (10,394 MI hospitalizations), and from beneficiaries with Medicare Advantage (176,268 MI hospitalizations). The proportion of beneficiaries who had their LDL-C measured following MI hospital discharge was estimated accounting for the competing risk of death.
Results
In the primary analysis (mean age 76.9 years, 84.4% non-Hispanic White), 29.9% of beneficiaries had their LDL-C measured within 90 days following MI hospital discharge. Among Hispanic, Asian, non-Hispanic White, and non-Hispanic Black beneficiaries, the 90-day postdischarge LDL-C testing was 33.8%, 32.5%, 30.0%, and 26.0%, respectively. Postdischarge LDL-C testing within 90 days was highest in the Middle Atlantic (36.4%) and lowest in the West North Central (23.4%) U.S. regions. In secondary analyses, the 90-day postdischarge LDL-C testing was 26.9% among beneficiaries with fee-for-service coverage without pharmacy benefits, and 28.6% among beneficiaries with Medicare Advantage coverage.
Conclusions
LDL-C testing following MI hospital discharge among Medicare beneficiaries was low.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Center for Observational Research, Amgen Inc, Thousand Oaks, California, USA.
- ICON Clinical Research Inc, Blue Bell, Pennsylvania, USA.
- Amgen Inc, Thousand Oaks, California, USA.
- Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Förderung
- Amgen Inc
Zitieren
APA
Colantonio, L. D., Wang, Z., Jones, J., Dhalwani, N. N., Shannon, E. D., Liu, C., Kalich, B. A., Muntner, P., Rosenson, R. S., & Bittner, V. (2024). Low-Density Lipoprotein Cholesterol Testing Following Myocardial Infarction Hospitalization Among Medicare Beneficiaries. JACC: Advances, 3(1), 100753. https://doi.org/10.1016/j.jacadv.2023.100753
Vancouver
Colantonio LD, Wang Z, Jones J, Dhalwani NN, Shannon ED, Liu C, et al. Low-Density Lipoprotein Cholesterol Testing Following Myocardial Infarction Hospitalization Among Medicare Beneficiaries. JACC: Advances. 2024;3(1):100753. doi:10.1016/j.jacadv.2023.100753
BibTeX
@article{Colantonio2024,
author = {Colantonio, Lisandro D and Wang, Zhixin and Jones, Jenna and Dhalwani, Nafeesa N and Shannon, Erin D and Liu, Cici and Kalich, Bethany A and Muntner, Paul and Rosenson, Robert S and Bittner, Vera},
title = {Low-Density Lipoprotein Cholesterol Testing Following Myocardial Infarction Hospitalization Among Medicare Beneficiaries},
journal = {JACC: Advances},
year = {2024},
volume = {3},
number = {1},
pages = {100753},
doi = {10.1016/j.jacadv.2023.100753}
}
EUVIMED